CoChat

MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy

Mohajeri, Mohammad, Banach, Maciej, Atkin, Stephen L., Butler, Alexandra E., Ruscica, Massimiliano, Watts, Gerald F., Sahebkar, Amirhossein · 2018 · Trends in Pharmacological Sciences
Cited by 48

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tips.2018.09.005

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 89

  1. Krol, 2010, The widespread regulation of microRNA biogenesis, function and decay, Nat. Rev. Genet., 11, 597, 10.1038/nrg2843 · DOI · Paper page
  2. Garzon, 2009, MicroRNAs in cancer, Annu. Rev. Med., 60, 167, 10.1146/annurev.med.59.053006.104707 · DOI · Paper page
  3. Borchert, 2006, RNA polymerase III transcribes human microRNAs, Nat. Struct. Mol. Biol., 13, 1097, 10.1038/nsmb1167 · DOI · Paper page
  4. Berezikov, 2008, Exploring conservation of transcription factor binding sites with CONREAL, Methods Mol. Biol., 395, 437, 10.1007/978-1-59745-514-5_27 · DOI
  5. MacRae, 2007, Structural determinants of RNA recognition and cleavage by Dicer, Nat. Struct. Mol. Biol., 14, 934, 10.1038/nsmb1293 · DOI · Paper page
  6. Ambros, 2003, MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing, Cell, 113, 673, 10.1016/S0092-8674(03)00428-8 · DOI · Paper page
  7. Yang, 2005, Dicer is required for embryonic angiogenesis during mouse development, J. Biol. Chem., 280, 9330, 10.1074/jbc.M413394200 · DOI · Paper page
  8. Dessi, 2013, Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated fatty acids, ISRN Inflamm., 2013, 191823
  9. Graham, 2012, Dyslipidemias in the prevention of cardiovascular disease: risks and causality, Curr. Cardiol. Rep., 14, 709, 10.1007/s11886-012-0313-7 · DOI
  10. Neth, 2013, MicroRNAs in flow-dependent vascular remodelling, Cardiovasc. Res., 99, 294, 10.1093/cvr/cvt096 · DOI
  11. Raitoharju, 2013, MicroRNAs in the atherosclerotic plaque, Clin. Chem., 59, 1708, 10.1373/clinchem.2013.204917 · DOI
  12. Raitoharju, 2011, miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study, Atherosclerosis, 219, 211, 10.1016/j.atherosclerosis.2011.07.020 · DOI · Paper page
  13. Du, 2012, Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification, Arterioscler. Thromb. Vasc. Biol., 32, 2580, 10.1161/ATVBAHA.112.300206 · DOI
  14. Fan, 2014, MicroRNA-21 is a unique signature associated with coronary plaque instability in humans by regulating matrix metalloproteinase-9 via reversion-inducing cysteine-rich protein with Kazal motifs, Exp. Mol. Pathol., 96, 242, 10.1016/j.yexmp.2014.02.009 · DOI
  15. Bianconi, 2018, The regulation and importance of monocyte chemoattractant protein-1, Curr. Opin. Hematol., 25, 44, 10.1097/MOH.0000000000000389 · DOI · Paper page
  16. Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  17. Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N. Engl. J. Med., 359, 2195, 10.1056/NEJMoa0807646 · DOI · Paper page
  18. Hsu, 2012, Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver, J. Clin. Invest., 122, 2871, 10.1172/JCI63539 · DOI · Paper page
  19. Tsai, 2012, MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis, J. Clin. Invest., 122, 2884, 10.1172/JCI63455 · DOI · Paper page
  20. Sacco, 2012, MicroRNAs: emerging roles in lipid and lipoprotein metabolism, Curr. Opin. Lipidol., 23, 220, 10.1097/MOL.0b013e3283534c9f · DOI · Paper page
  21. Gatfield, 2009, Integration of microRNA miR-122 in hepatic circadian gene expression, Genes Dev., 23, 1313, 10.1101/gad.1781009 · DOI · Paper page
  22. Krützfeldt, 2005, Silencing of microRNAs in vivo with ‘antagomirs’, Nature, 438, 685, 10.1038/nature04303 · DOI · Paper page
  23. Sun, 2014, MicroRNA-management of lipoprotein homeostasis, Circ. Res., 115, 2, 10.1161/CIRCRESAHA.114.304228 · DOI
  24. Linsel-Nitschke, 2005, HDL as a target in the treatment of atherosclerotic cardiovascular disease, Nat. Rev. Drug Discov., 4, 193, 10.1038/nrd1658 · DOI · Paper page
  25. Goedeke, 2014, miRNA regulation of lipoprotein metabolism, Curr. Opin. Lipidol., 25, 282, 10.1097/MOL.0000000000000094 · DOI · Paper page
  26. Irani, 2016, MicroRNA-30c mimic mitigates hypercholesterolemia and atherosclerosis in mice, J. Biol. Chem., 291, 18397, 10.1074/jbc.M116.728451 · DOI
  27. Wang, 2012, [The influence of statin therapy on circulating microRNA-92a expression in patients with coronary heart disease], Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 24, 215
  28. Takahashi, 2010, Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin–angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels, Clin. Sci., 119, 395, 10.1042/CS20100003 · DOI · Paper page
  29. Takwi, 2012, A statin-regulated microRNA represses human c-Myc expression and function, EMBO Mol. Med., 4, 896, 10.1002/emmm.201101045 · DOI · Paper page
  30. Tu, 2013, MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention, Cell. Physiol. Biochem., 31, 997, 10.1159/000350117 · doi:10.1159/000350117
  31. Hu, 2013, Altered microRNA expression in the ischemic–reperfusion spinal cord with atorvastatin therapy, J. Pharmacol. Sci., 121, 343, 10.1254/jphs.12235SC · doi:10.1254/jphs.12235sc
  32. Rodrigues, 2009, Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells, Eur. J. Pharm. Sci., 37, 486, 10.1016/j.ejps.2009.04.006 · DOI
  33. Rodrigues, 2016, Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells, Eur. J. Pharm. Sci., 93, 431, 10.1016/j.ejps.2016.08.044 · DOI
  34. Zhang, 2016, Pitavastatin differentially modulates microRNA-associated cholesterol transport proteins in macrophages, PLoS One, 11
  35. Ma, 2012, Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130, Nat. Commun., 3, 1291, 10.1038/ncomms2276 · DOI
  36. Pan, 2009, MicroRNAs regulate CYP3A4 expression via direct and indirect targeting, Drug Metab. Dispos., 37, 2112, 10.1124/dmd.109.027680 · DOI · Paper page
  37. Liu, 2016, The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin, Sci. Rep., 6, 26544, 10.1038/srep26544 · DOI
  38. Pocathikorn, 2010, Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells, Clin. Exp. Pharmacol. Physiol., 37, 471, 10.1111/j.1440-1681.2009.05337.x · DOI
  39. Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscle. Thromb. Vasc. Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  40. Welder, 2010, High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol, J. Lipid Res., 51, 2714, 10.1194/jlr.M008144 · DOI · Paper page
  41. Zambrano, 2015, Impact of 3’UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study, Int. J. Clin. Exp. Med., 8, 5978
  42. Zambrano, 2015, Altered microRNome profiling in statin-induced HepG2 cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment, Cardiovasc. Drugs Ther., 29, 509, 10.1007/s10557-015-6627-0 · DOI
  43. Stormo, 2014, RNA-sequencing analysis of HepG2 cells treated with atorvastatin, PLoS One, 9, 10.1371/journal.pone.0105836 · DOI
  44. Libby, 2012, Inflammation in atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 32, 2045, 10.1161/ATVBAHA.108.179705 · DOI · Paper page
  45. Swirski, 2013, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure, Science, 339, 161, 10.1126/science.1230719 · DOI · Paper page
  46. Nakasa, 2008, Expression of microRNA-146 in rheumatoid arthritis synovial tissue, Arthritis Rheum., 58, 1284, 10.1002/art.23429 · DOI · Paper page
  47. Taganov, 2006, NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses, Proc. Natl. Acad. Sci. U. S. A., 103, 12481, 10.1073/pnas.0605298103 · DOI · Paper page
  48. Chen, 2007, A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection, J. Biol. Chem., 282, 28929, 10.1074/jbc.M702633200 · DOI · Paper page
  49. Satoh, 2012, Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal, Immunobiology, 217, 533, 10.1016/j.imbio.2011.08.005 · DOI
  50. Gojova, 2003, Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice, Blood, 102, 4052, 10.1182/blood-2003-05-1729 · DOI · Paper page
  51. Liu, 2008, CX 3 CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden, Arterioscler. Thromb. Vasc. Biol., 28, 243, 10.1161/ATVBAHA.107.158675 · DOI · Paper page
  52. Bobryshev, 1997, Ultrastructural evidence for association of vascular dendritic cells with T-lymphocytes and with B-cells in human atherosclerosis, J. Submicrosc. Cytol. Pathol., 29, 209
  53. Liu, 2015, Induction of dendritic cell–mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin A5, Arterioscler. Thromb. Vasc. Biol., 35, 197, 10.1161/ATVBAHA.114.304342 · DOI
  54. Frostegård, 2016, Oxidized low-density lipoprotein (OxLDL)–treated dendritic cells promote activation of T cells in human atherosclerotic plaque and blood, which is repressed by statins: microRNA let-7c is integral to the effect, J. Am. Heart Assoc., 5, 10.1161/JAHA.116.003976 · DOI · Paper page
  55. Giubilato, 2011, Expansion of CD4+ CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus, Eur. Heart J., 32, 1214, 10.1093/eurheartj/ehq499 · DOI · Paper page
  56. Sun, 2012, Role of unusual CD4+ CD28− T cells in acute coronary syndrome, Mol. Biol. Rep., 39, 3337, 10.1007/s11033-011-1103-9 · DOI
  57. Soejima, 2003, Preference toward a T-helper type 1 response in patients with coronary spastic angina, Circulation, 107, 2196, 10.1161/01.CIR.0000066317.23972.CE · DOI
  58. Xie, 2014, Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway, Cardiovasc. Ther., 32, 276, 10.1111/1755-5922.12098 · DOI
  59. Scheffer, 2008, Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study, Clin. Chem., 54, 1325, 10.1373/clinchem.2008.103234 · DOI · Paper page
  60. Zhang, 2008, The cell growth suppressor, mir-126, targets IRS-1, Biochem. Biophys. Res. Commun., 377, 136, 10.1016/j.bbrc.2008.09.089 · DOI · Paper page
  61. Fish, 2008, miR-126 regulates angiogenic signaling and vascular integrity, Dev. Cell, 15, 272, 10.1016/j.devcel.2008.07.008 · DOI · Paper page
  62. Wang, 2008, The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis, Dev. Cell, 15, 261, 10.1016/j.devcel.2008.07.002 · DOI · Paper page
  63. Xu, 2014, Effects of pitavastatin on the expression of VCAM-1 and its target gene miR-126 in cultured human umbilical vein endothelial cells, Cardiovasc. Ther., 32, 193, 10.1111/1755-5922.12081 · DOI
  64. Pan, 2017, Atorvastatin upregulates the expression of miR-126 in apolipoprotein e-knockout mice with carotid atherosclerotic plaque, Cell. Mol. Neurobiol., 37, 29, 10.1007/s10571-016-0331-x · DOI
  65. Li, 2014, Chitosan oligosaccharides downregulate the expression of E-selectin and ICAM-1 induced by LPS in endothelial cells by inhibiting MAP kinase signaling, Int. J. Mol. Med., 33, 392, 10.3892/ijmm.2013.1589 · doi:10.3892/ijmm.2013.1589
  66. Yang, 2015, VCAM-1-targeted silica nanoparticles doped with FITC and Fe3O4 for dual-mode cellular imaging of LPS-induced inflammatory endothelial cells, J. Control. Release, 213, e40, 10.1016/j.jconrel.2015.05.065 · doi:10.1016/j.jconrel.2015.05.065
  67. Ota, 2010, SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis, J. Atheroscler. Thromb., 17, 431, 10.5551/jat.3525 · DOI
  68. Jing, 2017, Pitavastatin up-regulate eNOS production by suppressing miR-155 expression in lipopolysaccharide-stimulated human umbilical vein endothelial cells, Cardiovasc. Ther., 35, 10.1111/1755-5922.12282 · DOI
  69. Sun, 2012, Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase, Hypertension, 60, 1407, 10.1161/HYPERTENSIONAHA.112.197301 · DOI · Paper page
  70. Yang, 2016, Activation of activator protein 2 alpha by aspirin alleviates atherosclerotic plaque growth and instability in vivo, Oncotarget, 7, 52729, 10.18632/oncotarget.10400 · DOI
  71. Li, 2016, Inhibition of aberrant microRNA-133a expression in endothelial cells by statin prevents endothelial dysfunction by targeting GTP cyclohydrolase 1 in vivo, Circulation, 134, 1752, 10.1161/CIRCULATIONAHA.116.017949 · DOI
  72. Minami, 2009, Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease, Eur. J. Clin. Invest., 39, 359, 10.1111/j.1365-2362.2009.02110.x · DOI · Paper page
  73. Zhang, 2011, Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease, Biochem. Biophys. Res. Commun., 405, 42, 10.1016/j.bbrc.2010.12.119 · DOI
  74. Liu, 2012, Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus, Arterioscler. Thromb. Vasc. Biol., 32, 2131, 10.1161/ATVBAHA.112.253385 · DOI
  75. Tsimokha, 2014, DNA damage modulates interactions between microRNAs and the 26S proteasome, Oncotarget, 5, 3555, 10.18632/oncotarget.1957 · DOI
  76. Ludwig, 2005, Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells, Biochem. Pharmacol., 70, 520, 10.1016/j.bcp.2005.04.046 · DOI
  77. Murray, 2002, The effects of lovastatin on proteasome activities in highly purified rabbit 20S proteasome preparations and mouse MC3T3-E1 osteoblastic cells, Metabolism, 51, 1153, 10.1053/meta.2002.34706 · doi:10.1053/meta.2002.34706
  78. Wang, 2017, Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors, Oncotarget, 8, 9021, 10.18632/oncotarget.14462 · DOI
  79. Ota, 2007, Sirt1 modulates premature senescence-like phenotype in human endothelial cells, J. Mol. Cell. Cardiol., 43, 571, 10.1016/j.yjmcc.2007.08.008 · DOI · Paper page
  80. Potente, 2008, Emerging roles of SIRT1 in vascular endothelial homeostasis, Cell Cycle, 7, 2117, 10.4161/cc.7.14.6267 · DOI · Paper page
  81. Rane, 2009, Downregulation of miR-199a derepresses hypoxia-inducible factor-1α and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes, Circ. Res., 104, 879, 10.1161/CIRCRESAHA.108.193102 · DOI · Paper page
  82. Saunders, 2010, miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues, Aging (Albany NY), 2, 415, 10.18632/aging.100176 · DOI · Paper page
  83. Yamakuchi, 2008, miR-34a repression of SIRT1 regulates apoptosis, Proc. Natl. Acad. Sci. U. S. A., 105, 13421, 10.1073/pnas.0801613105 · DOI · Paper page
  84. Yamakuchi, 2009, MiR-34, SIRT1, and p53: the feedback loop, Cell Cycle, 8, 712, 10.4161/cc.8.5.7753 · DOI · Paper page
  85. Zhu, 2011, MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1, Cardiovasc. Res., 92, 75, 10.1093/cvr/cvr145 · DOI · Paper page
  86. Tabuchi, 2012, MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression, Clin. Sci., 123, 161, 10.1042/CS20110563 · DOI · Paper page
  87. Garrido, 2012, Lysophosphatidic acid pretreatment prevents micromolar atorvastatin-induced endothelial cell death and ensures the beneficial effects of high-concentration statin therapy on endothelial gene expression, Ann. Vasc. Surg., 26, 549, 10.1016/j.avsg.2012.01.005 · doi:10.1016/j.avsg.2012.01.005
  88. Li, 2017, Atheroprotective effects of statins in patients with unstable angina by regulating the blood-borne microRNA network, Mol. Med. Rep., 16, 817, 10.3892/mmr.2017.6616 · DOI
  89. Allen, 2017, Pleiotropic and adverse effects of statins—do epigenetics play a role?, J. Pharmacol. Exp. Ther., 362, 319, 10.1124/jpet.117.242081 · DOI

Cited by

Metadata

Authors
Mohajeri, M., Banach, M., Atkin, S. L., Butler, A. E., Ruscica, M., Watts, G. F., & Sahebkar, A.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2018-11
Volume
39
Issue
11
Pages
967-981
ISSN
0165-6147
Cited by
48
References
11
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.